

MARKSANS PHARMA LIMITED

Regd. Office: 11th Floor, Lotus Business Park Off. New Link Road, Andheri (West), Mumbai-400053

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2011

Rs. in Lacs

Sr. No.	PARTICULARS	For the quarter ended on			For the period ended on			For the year ended on
		31.12.2011 (UNAUDITED)	30.09.2011 (UNAUDITED)	31.12.2010 (UNAUDITED)	31.12.2011 (UNAUDITED)	31.12.2010 (UNAUDITED)	31.12.2010 (UNAUDITED)	31st March 11 (AUDITED)
1	Income							
a>	Net Sales/ Income from Operations	8,861.13	9,799.63	7,534.48	26,014.40	22,818.83	30,531.80	
b>	Other Operating Income	26.75	52.12	33.59	84.07	73.28	175.06	
	Total Income	8,887.88	9,851.75	7,568.07	26,098.47	22,892.11	30,706.86	
2	Expenditure							
a>	(Increase)/Decrease in stock in trade	(1.38)	0.14	(105.01)	(3.41)	98.37	(45.33)	
b>	Consumption of Material & Purchases	6,340.79	5,381.03	5,366.19	16,248.29	15,290.79	20,324.89	
c>	Employee Cost	1,260.44	1,026.71	979.19	3,318.77	2,609.55	3,625.61	
d>	Depreciation	440.43	1,444.70	119.31	2,233.79	575.21	1,997.52	
e>	Other Expenditure	6,526.99	1,693.71	924.52	9,383.53	2,717.68	7,306.31	
	Total Expenditure	14,567.27	9,546.29	7,284.20	31,180.97	21,291.60	33,209.00	
3	Profit from Operations before other income, Interest & Exceptional Items (1-2)	(5,679.39)	305.46	283.87	(5,082.50)	1,600.51	(2,502.14)	
4	Other Income	-	-	-	-	-	-	
5	Profit before Interest & Exceptional Item (3+4)	(5,679.39)	305.46	283.87	(5,082.50)	1,600.51	(2,502.14)	
6	Interest	507.71	381.14	420.92	1,227.16	1,554.63	11,020.56	
7	Profit after Interest but before Tax & Exceptional items	(6,187.10)	(75.68)	(137.05)	(6,309.66)	45.88	(13,522.70)	
8	Exceptional items	-	-	-	-	-	-	
9	Profit/(Loss) from Ordinary activities before Tax (7+8)	(6,187.10)	(75.68)	(137.05)	(6,309.66)	45.88	(13,522.70)	
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	-	-	-	-	-	641.36	
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	(6,187.10)	(75.68)	(137.05)	(6,309.66)	45.88	(14,164.06)	
12	a> Less:- Minority Interest	26.66	18.62	31.98	94.70	63.14	138.71	
b>	Less: Extraordinary Item-(Loss)/Profit on sale of division/Fixed assets	-	-	175.83	-	(7,936.39)	(8,021.68)	
13	Net Profit/ (Loss) for the period (11-12)	(6,213.76)	(94.30)	6.80	(6,404.36)	(7,953.65)	(22,324.45)	
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.07	3,678.07	3,678.07	3,678.07	3,678.07	3,678.07	
15	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year	-	-	-	-	-	6,216.30	
16	a> Earnings Per Share (Basic & Diluted) (before extraordinary items.Rs.)	(1.68)	(0.02)	(0.04)	(1.72)	0.01	(3.85)	
b>	Earnings Per Share(Basic & Diluted) (after Extraordinary items- Rs.)	(1.69)	(0.03)	0.002	(1.74)	(2.16)	(6.07)	
17	Public Shareholding:							
	- Number of Shares	189,823,694	189,823,694	189,823,694	189,823,694	189,823,694	189,823,694	
	- Percentage of Holding	51.61%	51.61%	51.61%	51.61%	51.61%	51.61%	
18	Promoters and Promoter group Shareholdings	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	
a>	Pledged/Encumbered	-	-	-	-	-	-	
	- Number of Shares	NIL	NIL	NIL	NIL	NIL	NIL	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N.A	N.A	N.A	N.A	N.A	N.A	
	- Percentage of Holding (as a % of the total share capital of the Company)	N.A	N.A	N.A	N.A	N.A	N.A	
b>	Non-encumbered	-	-	-	-	-	-	
	- Number of Shares	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%	100%	
	- Percentage of Holding (as a % of the total share capital of the Company)	48.39%	48.39%	48.39%	48.39%	48.39%	48.39%	



MARKSANS PHARMA LIMITED

Regd. Office: 11th Floor, Lotus Business Park Off. New Link Road, Andheri (West), Mumbai-400053

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER ENDED 31ST DECEMBER, 2011

Rs. in Lacs

Sr. No.	PARTICULARS	For the quarter ended on			For the period ended on			For the year ended on 31st March 11 (AUDITED)
		31.12.2011 (UNAUDITED)	30.09.2011 (UNAUDITED)	31.12.2010 (UNAUDITED)	31.12.2011 (UNAUDITED)	31.12.2010 (UNAUDITED)	31.12.2010 (UNAUDITED)	
1	Income							
	a>. Net Sales/ Income from Operations	3,117.23	5,001.77	3,492.83	11,418.15	12,143.30	15,543.76	
	b>. Other Operating Income	24.74	50.58	31.89	77.95	68.57	168.64	
	Total Income	3,141.97	5,052.35	3,524.72	11,496.10	12,211.87	15,712.40	
2	Expenditure							
	a>. (Increase)/Decrease in stock in trade	(1.38)	0.14	2.74	(3.41)	(1.93)	3.55	
	b>. Consumption of Material & Purchases	2,666.06	2,266.82	2,815.14	6,776.80	8,571.78	10,728.29	
	c>. Employee Cost	350.20	309.20	290.57	972.41	815.19	1,137.68	
	d>. Depreciation	86.27	1,410.01	88.06	1,810.20	482.70	1,464.39	
	e>. Other Expenditure	5,787.26	997.80	353.90	7,395.00	1,147.49	5,074.43	
	Total Expenditure	8,888.41	4,983.97	3,550.41	16,951.00	11,015.23	18,408.34	
3	Profit from Operations before other income, Interest & Exceptional Items (1-2)	(5,746.44)	68.38	(25.69)	(5,454.90)	1,196.64	(2,695.94)	
4	Other Income	-	-	-	-	-	-	
5	Profit before Interest & Exceptional Item (3+4)	(5,746.44)	68.38	(25.69)	(5,454.90)	1,196.64	(2,695.94)	
6	Interest	307.67	286.36	357.22	847.26	1,252.58	10,576.67	
7	Profit after Interest but before Tax & Exceptional Items	(6,054.11)	(217.98)	(382.91)	(6,302.16)	(55.94)	(13,272.61)	
8	Exceptional Items	-	-	-	-	-	-	
9	Profit/(Loss) from Ordinary activities before Tax (7+8)	(6,054.11)	(217.98)	(382.91)	(6,302.16)	(55.94)	(13,272.61)	
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	-	-	-	-	-	484.63	
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	(6,054.11)	(217.98)	(382.91)	(6,302.16)	(55.94)	(13,757.24)	
12	Less: Extraordinary Item-(Loss)/Profit on sale of division/Fixed assets	-	-	175.83	-	(7,936.39)	(8,021.68)	
13	Net Profit/(Loss) for the period (11-12)	(6,054.11)	(217.98)	(207.08)	(6,302.16)	(7,992.33)	(21,778.92)	
14	Paid up Equity Share Capital (Face Value Re.1 each)	3,678.07	3,678.07	3,678.07	3,678.07	3,678.07	3,678.07	
15	Reserve Excluding Revaluation Reserve as per Balance Sheet of Previous Accounting year	-	-	-	-	-	6,031.23	
16	a>. Earnings Per Share (Basic & Diluted) (before extraordinary items, Rs.)	(1.65)	(0.06)	(0.10)	(1.71)	(0.02)	(3.74)	
	b>. Earnings Per Share (Basic & Diluted) (after Extraordinary items- Rs.)	(1.65)	(0.06)	(0.06)	(1.71)	(2.17)	(5.92)	
17	Public Shareholding:							
	- Number of Shares	189,823,694	189,823,694	189,823,694	189,823,694	189,823,694	189,823,694	
	- Percentage of Holding	51.61%	51.61%	51.61%	51.61%	51.61%	51.61%	
18	Promoters and Promoter group Shareholdings	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	
	a>- Pledged/Encumbered	NIL	NIL	NIL	NIL	NIL	NIL	
	- Number of Shares	N/A	N/A	N/A	N/A	N/A	N/A	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N/A	N/A	N/A	N/A	N/A	N/A	
	- Percentage of Holding (as a % of the total share capital of the Company)	N/A	N/A	N/A	N/A	N/A	N/A	
	b>- Non-encumbered	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	
	- Number of Shares	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	177,983,510	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%	100%	
	- Percentage of Holding (as a % of the total share capital of the Company)	48.39%	48.39%	48.39%	48.39%	48.39%	48.39%	



Notes:

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 13.02.2012.
- 2 The Company will consider the effect of Deferred Tax Assets/(Liabilities) - AS 22 in the audited accounts at the year end.
- 3 The entire net worth of the Company as on 31st March, 2011 has eroded. Therefore, as required under the provisions of the Sick Industrial Companies (Special Provisions) Act, 1985, the Company has made a reference to the Board for Industrial and Financial Reconstruction (BIFR) for determining measures that will be adopted with respect to the Company.
- 4 The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- 5 There were no pending investor complaints at the beginning and end of the Quarter. The Company has not received any investor complaint during the Quarter.
- 6 Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.
- 7 The Company identifies impairable assets at the year end for the purpose of arriving at impairment loss.

Place: Mumbai.

Date: 13.02.2012

Visit us at www.marksanspharma.com

For MARKSANS PHARMA LIMITED



MARK SALDANHA
Managing Director.



N. K. MITTAL & ASSOCIATES

CHARTERED ACCOUNTANTS

817, Bldg. No. 3, Navjivan Commercial Premises Co.-op. Soc., Lamington Rd., Mumbai Central (E), Mumbai - 400 008.

☎ : 2309 6121 • Mob. : 98926 40589 • E-mail : ca_mittal@rediffmail.com • nkmittalandassociates@gmail.com

N. K. Mittal

B.Com, FCA, LLB, EMBA

LIMITED REVIEW REPORT FOR THE PERIOD ENDED 31.12.2011

We have reviewed the accompanying statement of unaudited financial results of MARKSANS PHARMA LTD for the period ended 31st Dec, 2011 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards¹ and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. K. MITTAL & ASSOCIATES

Chartered Accountants

N.K. MITTAL

(Proprietor)

M.No.46785

Place: Mumbai

Date: 13.02.2012

